ViiV Healthcare recently finalized its acquisition of a portfolio with HIV research and development information from Bristol-Myers Squibb.
The portfolio contains several programs that are currently in varying stages of clinical and preclinical development. There are also programs in the discovery stage.
The acquisition, which cost ViiV Healthcare $350 million, also benefits Bristol-Myers Squibb. The company will receive regulatory milestone and potential development payments amounting to $518 million. This is for Bristol-Myers Squibb’s clinical assets. For preclinical and discovery programs, the company could receive $587 million from ViiV.
As soon as the products are approved and marketed, ViiV Healthcare will also pay tiered royalties to Bristol-Myers Squibb. There will be sales-based milestone payments up to $750 million for each individual clinical asset and up to $700 million for each individual pre-clinical and discovery program.
The acquisition and agreements will not change the marketed HIV medicines currently under Bristol-Myers Squibb, including Evotaz, Reyataz, Atripla, and Sustiva. This will allow patients who need these medicines to continue using them to manage their HIV infections.